TICKERNERD
Menu
NRIXNRIXHealthcare · Biotechnology

NRIX Stock Forecast: Nurix Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$24
+6.96% on the day

The 14 Wall Street analysts covering Nurix Therapeutics, Inc. hold a median 12-month price target of $34 — +43.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 13 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.3B
Ticker Nerd rank
93 / 100
Median analyst target
$34
Analysts covering
14
Revenue$9.0M−79.5% y/y
Operating income−$94.2M
Net income−$89.5M
Free cash flow−$98.5M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.1%
1M
−7.2%
YTD
+24.8%
1Y
+157.8%
From 52W high
−14.8%
From 52W low
+157.8%
$9
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nurix Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
98
Value
98
Momentum
97
Revisions
79
Accruals
48
Volatility
37
Size
33
Issuance
19

Growth (99): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26NRIXHigh $45Median $34Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $25Median $34High $45

The green dot is the last close — the median target sits +43.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Aug 2026RBC CapitalMaintainsOutperform$33 → $36
4 Aug 2026NeedhamReiteratesBuy$34
28 July 2026Morgan StanleyMaintainsOverweight$36 → $38
28 July 2026Morgan StanleyMaintainsOverweight—
22 July 2026UBSMaintainsBuy—
22 July 2026UBSMaintainsBuy$23 → $31
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$30 → $34
10 July 2026BTIGReiteratesBuy$32
10 July 2026BTIGReiteratesBuy—
10 July 2026HC Wainwright & Co.MaintainsBuy$32 → $34
10 July 2026HC Wainwright & Co.MaintainsBuy—
10 July 2026NeedhamReiteratesBuy—
10 July 2026NeedhamReiteratesBuy$34
10 July 2026RBC CapitalMaintainsOutperform—
10 July 2026RBC CapitalMaintainsOutperform$30 → $33
10 July 2026StifelMaintainsBuy—
10 July 2026StifelMaintainsBuy$34 → $40
10 July 2026Truist SecuritiesMaintainsBuy$32 → $34
10 July 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NRIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Nurix Therapeutics, Inc. returned +157.8% against +17.5% for the S&P 500, dividends included.

NRIX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26NRIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Nurix Therapeutics, Inc. (NRIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.3×

Cheaper than 92% of US stocks

Price / sales
62.5×

Cheaper than 5% of US stocks

Price / book
5.7×

Cheaper than 17% of US stocks

EV / EBITDA
−5.4×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−79.5%

Higher than 3% of US stocks

Earnings growth (YoY)
−79.5%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1041.7%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−80.3%

Higher than 16% of US stocks

Return on assets
−40.1%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nurix Therapeutics, Inc. (NRIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nurix Therapeutics, Inc. has a market value of $2.3B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 31 May 2026: $36.8M. The latest quarter shrank 79.5% year on year.

  • Net income over the same four quarters: −$341.4M, a −928.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.45.

  • Free cash flow in the twelve months to 31 May 2026: −$304.5M, after $10.8M of capital spending.

  • Shares outstanding: 103.7M.

  • Trailing P/E: −7.3×; forward P/E: −20.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Nurix Therapeutics, Inc. employs 317 people — $116K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

NRIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRIXNurix Therapeutics, Inc.$2.3B
93
ADMAADMA Biologics, Inc.$2.3B
49
AUPHAurinia Pharmaceuticals, Inc.$2.2B
93
CLDXCelldex Therapeutics, Inc.$2.2B
27
NAMSNewAmsterdam Pharma Co. NV$2.3B
39
MBXMBX Biosciences, Inc.$2.3B
36
HRMYHarmony Biosciences Holdings, Inc.$2.1B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nurix Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRIX news & analysis

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Seeking Alpha · 14 Oct 2026positive

Seeking Alpha reports that Nurix initiated the phase 3 DAYBreak CLL-306 study to evaluate bexobrutideg against JAYPIRCA in relapsed/refractory CLL/SLL. The article cites phase 1/2 data and ongoing pivotal trials as supporting potential Accelerated Approval in third-line-or-later disease.

Why it matters — The study and potential approval pathway represent key clinical development milestones for Nurix’s bexobrutideg program in CLL/SLL.

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 12 Oct 2026positive

Nurix Therapeutics reported quarterly earnings of $4.73 per share, above the Zacks Consensus Estimate of a $0.56-per-share loss. This compares with a loss of $1.03 per share a year earlier.

Why it matters — NRIX watchers may note the reported earnings exceeded the consensus estimate and improved from the year-ago result.

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 12 Oct 2026positive

Nurix Therapeutics reported third-quarter 2026 financial results and a corporate update, including dosing the first patient in the registrational Phase 3 DAYBreak CLL-306 trial. The trial compares bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL.

Why it matters — The first patient dose marks the start of the registrational Phase 3 trial, a development relevant to Nurix’s clinical program in CLL/SLL.

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

GlobeNewsWire · 7 Oct 2026positive

Nurix Therapeutics announced enrollment of the first patient in the Phase 1b/2 NX-5948-203 study of bexobrutideg combined with venetoclax for CLL/SLL. The initial cohort will focus on relapsed/refractory disease, with potential expansion to first-line CLL.

Why it matters — The enrollment marks the start of clinical evaluation of this combination, including a strategy to assess bexobrutideg with venetoclax and selected Roche-portfolio antibodies.

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

GlobeNewsWire · 5 Oct 2026positive

Nurix Therapeutics and Gilead Sciences agreed to extend the research term for an undisclosed oncology program within their ongoing strategic collaboration by an additional two years. This extension builds on the relationship established in 2019, and Nurix retains co-development and 50/50 profit sharing options on up to two programs in the United States.

Why it matters — A NRIX watcher would care because the extended collaboration signals continued commitment from Gilead and preserves Nurix's co-development and profit-sharing options on up to two programs in the U.S.

FAQ

Frequently asked questions about NRIX stock

What is the NRIX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Nurix Therapeutics, Inc. have a median 12-month price target of $34, with estimates ranging from $25 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRIX stock a buy right now?

Of the 14 analysts covering Nurix Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nurix Therapeutics, Inc. 93 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRIX?

As at 13 Oct 2026, Nurix Therapeutics, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will NRIX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +43.6% from the last close, and Ticker Nerd's factor model ranks Nurix Therapeutics, Inc. 93 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRIX stock forecast for 2030?

No analyst covering Nurix Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $45 over the next 12 months.

How has NRIX stock performed over the past year?

Nurix Therapeutics, Inc. returned +157.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nurix Therapeutics, Inc. do?

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines.

What is the latest news on NRIX?

The most recent item we track (Seeking Alpha, 14 Oct 2026): "Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways". Seeking Alpha reports that Nurix initiated the phase 3 DAYBreak CLL-306 study to evaluate bexobrutideg against JAYPIRCA in relapsed/refractory CLL/SLL. The article cites phase 1/2 data and ongoing pivotal trials as supporting potential Accelerated Approval in third-line-or-later disease.

Company

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines. Nurix Therapeutics develops small-molecule and antibody-based therapies designed to modulate cellular protein levels through the ubiquitin-proteasome system, with applications in oncology, immunology, and inflammatory diseases. Its current pipeline includes investigational programs aimed at B-cell malignancies, immune-mediated disorders, and other serious conditions, supported by its DELigase discovery platform and expertise in E3 ligases. The company also advances partnered research and development programs with major pharmaceutical collaborators, combining internal drug discovery capabilities with broader development and commercialization efforts. Headquartered in San Francisco, California, Nurix Therapeutics plays a specialized role in the biotechnology market by translating protein degradation science into potential therapeutic candidates for diseases with limited treatment options.

CEO Dr. Arthur T. Sands M.D., Ph.D. · 317 employees · United States · https://www.nurixtx.com